Calcitonin gene-related peptide-induced vasodilation in the human forearm is antagonized by CGRP8-37: evaluation of a human in vivo pharmacodynamic model

What Was Tested

The paper reports a study of CGRP (Calcitonin Gene-Related Peptide), published as a randomized controlled trial.

After a 90-minute washout period, CGRP infusions were repeated during coinfusion of CGRP8-37 (333 ng.min(-1).dL(-1) forearm) to assess inhibition by CGRP8-37.

To determine the antagonistic potency of CGRP8-37, a 4-period, placebo-controlled crossover study was conducted in 6 subjects, in which CGRP (10 ng.min(-1).dL(-1) forearm) was infused for 20 minutes together with placebo or CGRP8-37 (300, 600, or 1200 ng.min(-1).dL(-1) forearm).

Who Took Part

According to the abstract, 21 subjects were involved.

By PubMed's age tags, the people studied were adults, both men and women.

Forearm blood flow (FBF) responses to intra-arterial CGRP infusions were measured via venous occlusion plethysmography in 21 healthy subjects.

How the Study Was Run

In design terms this was a randomized, placebo-controlled and crossover study.

Because people in this CGRP (Calcitonin Gene-Related Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some subjects received a placebo instead of CGRP (Calcitonin Gene-Related Peptide), giving a reference point.

In the crossover set-up each of the subjects took both CGRP (Calcitonin Gene-Related Peptide) and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Calcitonin Gene-Related Peptide, Calcium Channel Blockers, Forearm, Hemodynamics, Nitroprusside, Peptide Fragments and Regional Blood Flow.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of CGRP (Calcitonin Gene-Related Peptide) in 21 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2006 (Clinical pharmacology and therapeutics), a journal based in United States.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, all human trials.